Real-World PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC

Published by W Butcher on

A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with overall survival (OS) among patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide or abiraterone. In a real-world setting, prostate-specific antigen value is used among practitioners to monitor treatment outcomes in patients with metastatic CRPC, however, due to possible spurious “flare” reactions, early prostate-specific antigen changes are not accounted for in the definition of prostate-specific antigen progression.

Read More…

Categories: Uncategorized